
Zomedica Corp. ZOM
Quarterly report 2025-Q3
added 11-04-2025
Country |
|
IPO year |
2017 |
Industry |
Drug manufacturers |
Stock Exchange |
NYSE AMERICAN |
Shares |
980 M |
Market Cap[1] |
$ 98 M |
EBITDA (LTM) |
$ -84.7 M |
P/E (LTM) |
- |
P/S (LTM) |
3.43 |
EPS (LTM) |
-0.1 |
Other stocks of industry "Drug manufacturers"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | Nasdaq Global Market | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | Nasdaq Capital Market | ||
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | Nasdaq Global Market,SPB | ||
|
Canopy Growth Corporation
CGC
|
$ 1.19 | - | $ 128 M | Nasdaq Global Select Market | ||
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | Nasdaq Global Market | ||
|
Cronos Group
CRON
|
$ 2.67 | -0.74 % | $ 1.42 B | Nasdaq Global Market | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | Nasdaq Capital Market | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | NYSE,SPB | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | Nasdaq Capital Market | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | Nasdaq Global Select Market | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | Nasdaq Global Market,SPB | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | NYSE | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | Nasdaq Global Select Market,SPB | ||
|
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | Nasdaq Capital Market | ||
|
Emergent BioSolutions
EBS
|
$ 13.9 | - | $ 712 M | NYSE,SPB | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | Nasdaq Global Select Market | ||
|
Avadel Pharmaceuticals plc
AVDL
|
$ 21.5 | - | $ 2.05 B | Nasdaq Global Select Market | ||
|
Evolus
EOLS
|
$ 5.66 | - | $ 351 M | Nasdaq Global Market | ||
|
Harrow Health
HROW
|
$ 51.0 | -4.67 % | $ 1.66 B | Nasdaq Global Market | ||
|
China Pharma Holdings
CPHI
|
$ 1.35 | 5.88 % | $ 23.6 M | NYSE American | ||
|
Sundial Growers
SNDL
|
$ 1.65 | - | $ 3.37 M | Nasdaq Global Select Market | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | Nasdaq Global Select Market | ||
|
OrganiGram Holdings
OGI
|
$ 1.68 | - | $ 402 M | Nasdaq Global Select Market | ||
|
Bausch Health Companies
BHC
|
$ 7.9 | 3.47 % | $ 2.88 B | NYSE | ||
|
Pacira BioSciences
PCRX
|
$ 26.0 | - | $ 1.2 B | Nasdaq Global Select Market,SPB | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | NYSE | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 5.19 | - | $ 73 M | Nasdaq Global Select Market | ||
|
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | Nasdaq Global Select Market | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 3.74 | -1.58 % | $ 4.64 M | Nasdaq Capital Market | ||
|
Organogenesis Holdings
ORGO
|
$ 4.3 | - | $ 566 M | Nasdaq Capital Market | ||
|
Aurora Cannabis
ACB
|
$ 4.24 | - | $ 86.3 M | NYSE | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | Nasdaq Global Select Market,SPB | ||
|
Veru
VERU
|
$ 2.37 | 1.72 % | $ 320 M | Nasdaq Capital Market | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | Nasdaq Global Select Market | ||
|
Perrigo Company plc
PRGO
|
$ 14.59 | -1.19 % | $ 2 B | NYSE | ||
|
ProPhase Labs
PRPH
|
- | - | $ 5.07 M | Nasdaq Capital Market | ||
|
Rockwell Medical
RMTI
|
$ 0.95 | 2.78 % | $ 22.2 M | Nasdaq Global Market | ||
|
cbdMD
YCBD
|
$ 1.1 | - | $ 4.74 M | NYSE American | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | Nasdaq Global Market | ||
|
Relmada Therapeutics
RLMD
|
$ 4.32 | 5.88 % | $ 130 M | Nasdaq Global Select Market,SPB | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | Nasdaq Global Select Market | ||
|
Assertio Holdings
ASRT
|
$ 9.43 | -1.05 % | $ 670 M | Nasdaq Capital Market | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | Nasdaq Capital Market | ||
|
Solid Biosciences
SLDB
|
$ 5.61 | - | $ 229 M | Nasdaq Global Select Market,SPB | ||
|
SCYNEXIS
SCYX
|
$ 0.64 | - | $ 30.6 M | Nasdaq Global Select Market | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | Nasdaq Global Select Market,SPB | ||
|
Tilray
TLRY
|
$ 8.99 | - | $ 5.56 B | Nasdaq Global Select Market | ||
|
TherapeuticsMD
TXMD
|
$ 2.04 | - | $ 21.3 M | Nasdaq Global Select Market | ||
|
Viatris
VTRS
|
$ 12.46 | - | $ 15.1 B | Nasdaq Global Select Market,SPB |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.